Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Analysis

The genome, microbiome and evolutionary medicine

Robert C. Brunham
CMAJ February 12, 2018 190 (6) E162-E166; DOI: https://doi.org/10.1503/cmaj.170846
Robert C. Brunham
University of British Columbia and British Columbia Centre for Disease Control, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Metrics
  • Responses
  • PDF
Loading
KEY POINTS
  • The practice of medicine will increasingly be based on an evolutionary understanding of the human genome and microbiome.

  • According to the evolutionary medicine framework, disease is conceptualized within six categories that capture genetic, evolutionary and mechanistic causes.

  • Evolutionary medicine views patients as individuals whose history has unfolded over the course of an entire life cycle with unique windows of vulnerability during which the environment affects genome expression; the microbiome has co-evolved with animal hosts and protected the host against pathogens, assisted in digestion of food and in the development of the immune system.

  • Although evolutionary medicine requires further research to develop its distinctive viewpoint, it offers a secure foundation for future developments in medicine.

The revolution in genomics is transforming medicine.1 Among its important contributions is a demonstration — through a greater understanding of the human genome and the microbiome — that evolutionary biology underpins the principles and practice of medicine. Evolutionary medicine provides the unifying framework by which clinical and public health physicians can incorporate genomics into medicine. It reconsiders the questions, “what is a patient?” and “what is a disease?” Some areas of medicine have already incorporated genomics and evolutionary medicine into clinical practice (e.g., the disciplines of genetics, infectious diseases and cancer care). Other areas of medicine are likely to follow as new research emerges, and the practice of medicine will be increasingly based on an evolutionary understanding of the human genome and microbiome.

What is evolutionary medicine’s view of disease?

The World Health Organization (WHO) lists about 12 000 diseases in its International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10). More than 6000 drugs are used in treatment, along with 2500 surgeries and 1500 other medical interventions.2 For evolutionary medicine, the causes of disease are more simply conceived.3 At the general level, diseases can result from extrinsic or intrinsic causes. At a finer level, six categories of disease are conceptualized that capture both evolutionary and mechanistic causes (Table 1), which will be discussed in more detail later.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1:

Disease categories in evolutionary medicine

How does evolutionary medicine view the patient?

Evolutionary medicine views patients as individuals whose history has unfolded over the course of an entire life cycle,4 beginning at fertilization and progressing through birth, growth, maturation and aging. Human life histories are remarkably uniform, but with unique windows of vulnerability during which the environment affects genome expression. In particular, fetal phase, infancy and childhood are uniquely vulnerable to environmental forces as shown in a review of studies on the developmental origin of disease.5 The remarkable expansion of the human lifespan occurring during the past century, which followed a dramatic reduction in childhood mortality, is an example of a trait that shows the plasticity of life history.6 Epigenomic studies may show the biochemistry that underpins the plasticity of lifespan and its responsiveness to early life events, which may have great potential for development of new treatments for chronic diseases.

Like all organisms, humans age. From an evolutionary perspective, aging exists because the chances of reproducing progressively decrease over time owing to the accumulated risk of death from extrinsic causes. Thus, there is stronger natural selection to maintain health at younger ages than at older ages, and this selection can favour genes that are beneficial in youth but detrimental in old age. Such genes produce antagonistic pleiotropy and tend to accumulate in the genome through evolutionary time.7 Many diseases of aging are thought to be due to the effects of antagonistic pleiotropic genes on intrinsic homeostatic and maintenance processes. The gene for interleukin-6 (IL-6) may be an example of antagonistic pleiotropy. Interleukin-6 is tightly regulated in early life but dysregulated in late life, and elevated levels of IL-6 are associated with several age-related chronic inflammatory diseases.8 Genomic and epigenomic studies of patterns of mortality among older adults should uncover those genes that display antagonistic pleiotropy.

How has the human genome evolved, and what are the implications for medicine?

A genome necessarily includes all protein-coding genes together with other functional and nonfunctional DNA elements that interact as an integrated entity that is vertically transmitted between generations.9 Although genes encode proteins, genomes encode organisms.10 Because segments of an individual genome are randomized at meiosis during gamete formation, genomes are assembled anew with each generation. Thus, it is genes and not genomes that are stable enough for natural selection to act on over evolutionary time scales. The evolutionary age of human genes varies considerably. About 20% are universal ancient genes with a subset of about 70 genes common to all cellular life on earth.11 Most of these genes are related to protein synthesis. About 40% of human genes are shared among all eukaryotes, which include metabolic and other genes essential to cellular function.11 Some genes have been shaped by billions of selection events and are finely tuned without variation in the human genome. Such genes are fixed parts of the genome and include metabolic genes, which had their origin between 1.6 and 3.9 billion years ago.3 Genes for other parts of the human body have a much more recent evolutionary origin and, correspondingly, have been shaped by far fewer selection events. These include genes for hairlessness, dark skin colour and abundant sweat glands, which originated during the last 2 million years of evolution within the genus Homo.12 Much genetic, phenotypic and fitness variation exists among these younger genes in the human genome.

Comparisons between genomes of chimpanzees and humans suggest that the origin of the genus Homo was characterized by the head-to-head fusion of two ancestral chromosomes to form human chromosome two, resulting in the reproductive isolation of descendents within the genus Homo.13 Phenotypic traits that evolved within the Homo lineage include delayed maturation, menopause and longevity, as well as changes in postnatal brain development resulting in the evolution of childhood with learning by imitation,14 descent of the larynx for the development of rich spoken language,15 reshaping of an opposable thumb for tool manipulation and enhanced T- and B-cell function,16 possibly enabling humans to live in higher-density social groups. Genome analysis is beginning to uncover the genetic basis for these distinctive Homo phenotypes.

Global spread of humans out of Africa over the last 70 000 years resulted in variations in genome–based disease resistance as new environments and pathogens were encountered.17 New diets were acquired, which in turn generated wide variation in genes underlying detoxification mechanisms involving the cytochrome P450 and the N-acetyl transferase systems.18 Because medicinal drug metabolism is based mostly on these systems, differences acquired during the global spread of humans partly explain the variation in therapeutic response to drugs and provides the scientific basis for precision medicine.19 The domestication of plants and animals beginning 10 000 years ago further altered diet and introduced new infectious diseases into human communities. Variations in the human genome have been correlated strongly with variations in susceptibility to infectious diseases.20

What is the role of the evolving microbiome?

Genomics has also elucidated the remarkable microbiome that coats all human mucosal surfaces with at least as many microbial cells as the number of somatic cells that compose the human body. The most varied microbiome is found in the gastrointestinal tract.21 The microbiome has co-evolved with animal hosts and protected the host against pathogens, and assisted in digestion of food and in the development of the immune system, which in turn enabled the growth of the body to large size during vertebrate evolution.

Originally, the physiologic function of the immune system may have been the management of the commensal microbiome. The immune system is based on molecular recognition of commensal and pathogenic microbes.22 Discriminating between the molecules of pathogens and the molecules of the microbiome selected for the development of the adaptive immune system occurred around 500 million years ago.23 The older innate immune system that recognizes conserved microbial molecules is controlled by genes that also regulate the relation between host and microbiome. Through mutations, these genes may produce proteins that cause a spectrum of inflammatory diseases such as ulcerative colitis and Crohn disease.24 The gastrointestinal microbiome at the phyla level is remarkably similar from human to human. However, at the species and strain level each microbiome is nearly unique to an individual. The diversity and metabolic phenotype of the microbiome changes over the human life cycle.21 In addition, characteristic changes in the microbiome have been correlated with a variety of diseases. There is speculation that different microbiomes produce different dominant metabolites, which, by methylating DNA or acetylating histones, epigenetically alter gene expression and thereby affect metabolism or immunity.25

What are the categories of disease causation according to evolutionary medicine?

Table 1 summarizes the six categories of disease causation according to evolutionary medicine. As medical, public health and societal efforts have reduced the burden of extrinsic causes of disease, diseases of intrinsic origin have become increasingly common. Intrinsic diseases result from imperfections in the evolution of genome owing to constraints, trade-offs, antagonistic pleiotropy and changes to the environment that occur faster than the genome is able to adapt.

Category 1: Diseases with extrinsic causes

Extrinsic causes of disease include infection, altered microbiomes, starvation and malnutrition, injuries, hypoxia, hypo- and hyperthermia, and exposure to noxious xenobiotics among others. Infectious diseases are a primary cause of category 1 diseases and offer one of the most striking examples of the impact of genomics on medicine.26 Evolutionary medicine previously uncovered the important concept of microbial trade-off between modes of transmission and evolution of virulence,27,28 and genomics showed how pathogens evolved virulence traits as they adopted horizontal modes of transmission. For example, extensive phylogenomic analysis of the pathogenic bacterial phylum Chlamydiae resolved its ancient evolutionary origins, core complement of genes, niche and tissue-specific genomic adaptations, evolved virulence mechanisms and those proteins that preferentially interact with the T-cell immune system.29–32

Genomics has also been used for tracing the evolutionary history of pathogens as they transmit within populations. A recent example illustrates the power of genome evolution to elucidate the origin and transmission of a tuberculosis (TB) outbreak.33 An outbreak of 41 cases of TB occurred in a medium-sized community in British Columbia over a three-year period. The outbreak was investigated epidemiologically and genomically. Figure 1A provides the epidemic curve. Initially, the outbreak appeared to be due to a single strain of TB, and it was unclear whether a “virulence” mutation in the TB genome or changes in social conditions of the community had occurred. Genomic analysis of the mutation patterns of TB isolates as they replicated within their individual hosts was used to discover the transmission pathway between hosts. This analysis showed that the outbreak was caused by two distinct lineages of Mycobacterium tuberculosis that existed in the community before the outbreak. Genomic analysis clearly showed the central importance of just three individuals in the transmission network (Figure 1B). Epidemiologic investigation of these individuals showed that the introduction of crack cocaine into this community likely triggered the outbreak.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

A) Cases of tuberculosis in the outbreak community in British Columbia (blue bars), and the green line represents cocaine-related police files from the RCMP. B) Putative transmission network constructed from whole-genome data for 32 patients shows that two distinct genomic lineages (A and B) produced the outbreak.33 Note: RCMP = Royal Canadian Mounted Police. From Gardy and colleagues,33 reproduced with permission.

Category 2: Diseases that reflect adverse effects of the body’s defenses

The defence system of the human body provides a large evolutionary benefit, in particular when the threat of infectious disease is high.34 However, the benefit diminishes when infectious disease is well-controlled; then the high cost of the defence system becomes apparent. Diseases in this category include autoimmune diseases, allergies and possibly behaviours such as obsessive–compulsive and anxiety disorders. It is notable how rapidly these diseases emerged during the 20th century as diseases in category 1 came under control.35

Category 3: Diseases of disordered homeostasis

When culture changes much more rapidly than the genome can respond, “mismatch” diseases occur. These may be unique to humans because of the dominance of culture. These include obesity, type 2 diabetes, atherosclerosis, hypertension and addictive behaviours.36 Although the epigenomic and gene–environment basis for mismatch diseases are yet to be fully uncovered, it seems that they occur when normal physiologic systems that have adjustable set points are locked into a pathologic state.37

Category 4: Diseases resulting from age-related loss of maintenance mechanisms

Age-related limitations in organ, tissue, and cellular repair, unregulated inflammation, impaired autophagy, failure to eliminate mis-folded protein, and loss of fidelity in genome repair38 are most likely due to the pathophysiological effects of genes that display antagonistic pleiotropy. Diseases characterized by neurodegeneration, sarcopenia and reduced renal function, as well as osteoporosis, arthritis, cancer, atherosclerosis and type 2 diabetes are associated with such processes. Relative to other species, humans are at high risk of cancer; evolutionary medicine explains that this occurs because of long postreproductive life in humans where natural selection has been too weak to select for highly efficient mechanisms of cancer prevention against random mutations in the somatic stem cell genome.39–41 The gene for p53 encodes for a tumour suppressor protein and is an example that displays antagonistic pleiotropy. p53 protects against cancer up to a level beyond which further increases accelerate death from aging.42

Category 5: Genetic, genomic and chromosomal diseases

Evolutionary genomics in medicine began with the identification of diseases that are caused by single gene mutation; more than 3600 Mendelian diseases have been identified.1 No specific defenses have evolved against these diseases, and natural section most often eliminated affected individuals from the population. As human mating with first and second cousins decreases, there seems to be a corresponding decline in the impact of recessive Mendelian diseases.43 However, many of these diseases recur in populations through repeated germline mutations because of the heterozygote advantage of the carrier state.44 The genetic bases for Mendelian disorders are being diagnosed increasingly by whole exome sequencing,45 and genome therapy based on clustered regularly interspaced short palindromic repeats (CRISPR) technology is an emerging therapeutic approach to genes that cause Mendelian disease.46

Disease processes that affect the complex biology of embryogenesis include chromosomal and major genomic disorders.47 Natural selection partially prevents these diseases through gamete and embryo quality control, such as oocytic atresia or spontaneous abortion. Modern obstetrical care screens for these diseases, and genomics now enables detection of fetal DNA in maternal blood and offers the prospect for improved control.48,49

Category 6: Maternal, paternal and fetal genetic conflict disorders

Human pregnancy is sustained by a highly invasive placenta, in which fetal tissue directly bathes and regulates maternal tissue, and the fetus shares only 50% of its genome with its mother. Fetal–maternal genetic conflict can occur.50 These disorders include intrauterine growth retardation, eclampsia and gestational diabetes. In addition, chromosomes of maternal and paternal origin in the fetus may come into conflict, possibly contributing to major mental disorders such as autism and schizophrenia. Both Prader–Willi and Angelman syndromes have nearly identical deletions involving chromosome 15 q11–13. Prader–Willi syndrome has a deletion in paternal chromosome 15 and carries a high risk of schizophrenia. Angelman syndrome has a deletion in maternal chromosome 15 and carries a high risk of autism.51,52

How can evolutionary medicine change our approach to practising medicine?

The essential advantage of evolutionary medicine is its unifying conceptualization of health and disease. As Theodosius Dobzhansky famously said, “Nothing in biology makes sense except in the light of evolution.”53 The same appears true of medicine.

The current explanatory framework for medicine is based on mechanism.54 However, there are at least as many mechanisms as there are genes in the genome. Students of medicine may be daunted by the sheer range of mechanism-based medicine. Evolutionary medicine has the potential to unify the teaching and learning of mechanism-based medicine. Increasingly, there are calls for medical schools to format curricula on an evolutionary medicine basis, although few have done so.4,55–57 By highlighting the importance of evolutionary medicine, the genomic revolution should help to drive this change.

Evolutionary medicine in combination with genomics is being used to guide research that will uncover the importance of the microbiome, epigenome, gene–environment interaction and antagonistic pleiotropy. Such discoveries may lead to new therapies. A major challenge for funding agencies is how best to take advantage of the evolutionary categories of disease causation in their funding priorities.

Applying evolutionary medicine to clinical practice will not be straightforward. Evolution focuses on genes and clinicians focus on patients. Health is not directly selected by natural selection; rather, it is an indirect effect of organisms selected for reproductive success. Health is the central goal of medicine. Although evolutionary medicine requires further research to develop its distinctive viewpoint, it does provide a secure foundation for future developments in medicine.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Lander ES
    . Initial impact of the sequencing of the human genome. Nature 2011;470:187–97.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Gwande A
    . The future of medicine. The Reith Lectures, BBC Radio 4;2014.
  3. ↵
    1. Stephen C,
    2. Medzhitov R
    . Evolutionary medicine. Sunderland (MA): Sinauer Associates; 2016.
  4. ↵
    1. Stearns SC
    . Evolutionary medicine: its scope, interest and potential. Proc Biol Sci 2012;279:4305–21.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Gluckman PD,
    2. Hanson MA,
    3. Cooper C,
    4. et al
    . Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008;359:61–73.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Meza R,
    2. Pourbohloul B,
    3. Brunham RC
    . Birth cohort patterns suggest that infant survival predicts adult mortality rates. J Dev Orig Health Dis 2010;1:174–83.
    OpenUrl
  7. ↵
    1. Williams G
    . Pleiotropy, natural selection, and the evolution of senescence. Evolution 1957;11:398–411.
    OpenUrlCrossRef
  8. ↵
    1. Ershler WB,
    2. Keller ET
    . Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000;51:245–70.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Crespi BJ
    . The emergence of human-evolutionary medical genomics. Evol Appl 2011;4:292–314.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Stencel A,
    2. Crespi B
    . What is a genome? Mol Ecol 2013;22:3437–43.
    OpenUrlCrossRef
  11. ↵
    1. Koonin E
    . The logic of chance: the nature and origin of biological evolution. Upper Saddle River (NJ): Pearson Education; 2012.
  12. ↵
    1. O’Bleness M,
    2. Searles VB,
    3. Varki A,
    4. et al
    . Evolution of genetic and genomic features unique to the human lineage. Nat Rev Genet 2012;13:853–66.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Stankiewicz P
    . One pedigree we all may have come from — Did Adam and Eve have the chromosome 2 fusion? Mol Cytogenet 2016;9:72.
    OpenUrl
  14. ↵
    1. Herrmann E,
    2. Call J,
    3. Hernandez-Lloreda MV,
    4. et al
    . Humans have evolved specialized skills of social cognition: the cultural intelligence hypothesis. Science 2007;317:1360–6.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Lieberman P
    . The evolution of human speech. Curr Anthropol 2007;48:39–66.
    OpenUrlCrossRef
  16. ↵
    1. Soto PC,
    2. Stein LL,
    3. Hurtado-Ziola N,
    4. et al
    . Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation. J Immunol 2010;184:4185–95.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Nielsen R,
    2. Akey JM,
    3. Jakobsson M,
    4. et al
    . Tracing the peopling of the world through genomics. Nature 2017;541:302–10.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Meyer UA,
    2. Zanger UM,
    3. Schwab M
    . Omics and drug response. Annu Rev Pharmacol Toxicol 2013;53:475–502.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Feero WG,
    2. Guttmacher AE,
    3. Collins FS
    . Genomic medicine — an updated primer. N Engl J Med 2010;362:2001–11.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Hill AV
    . Evolution, revolution and heresy in the genetics of infectious disease susceptibility. Philos Trans R Soc Lond B Biol Sci 2012;367:840–9.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Lynch SV,
    2. Pedersen O
    . The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369–79.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Belkaid Y,
    2. Hand TW
    . Role of the microbiota in immunity and inflammation. Cell 2014;157:121–41.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Cooper MD,
    2. Alder MN
    . The evolution of adaptive immune systems. Cell 2006;124:815–22.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Cho JH
    . The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008;8:458–66.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Mischke M,
    2. Plosch T
    . The gut microbiota and their metabolites: potential implications for the host epigenome. Adv Exp Med Biol 2016;902:33–44.
    OpenUrl
  26. ↵
    1. Relman DA
    . Microbial genomics and infectious diseases. N Engl J Med 2011;365:347–57.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Anderson RM,
    2. May RM
    . Population biology of infectious diseases: Part I. Nature 1979;280:361–7.
    OpenUrlCrossRefPubMed
  28. ↵
    1. May RM,
    2. Anderson RM
    . Population biology of infectious diseases: Part II. Nature 1979;280:455–61.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Collingro A,
    2. Tischler P,
    3. Weinmaier T,
    4. et al
    . Unity in variety — the pan-genome of the Chlamydiae. Mol Biol Evol 2011;28:3253–70.
    OpenUrlCrossRefPubMed
    1. Read TD,
    2. Brunham RC,
    3. Shen C,
    4. et al
    . Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res 2000;28:1397–406.
    OpenUrlCrossRefPubMed
    1. Harris SR,
    2. Clarke IN,
    3. Seth-Smith HM,
    4. et al
    . Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nature genetics 2012;44: 413–9, S1.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Karunakaran KP,
    2. Rey-Ladino J,
    3. Stoynov N,
    4. et al
    . Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. J Immunol 2008;180:2459–65.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Gardy JL,
    2. Johnston JC,
    3. Ho Sui SJ,
    4. et al
    . Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 2011;364:730–9.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Kondrashova A,
    2. Seiskari T,
    3. Ilonen J,
    4. et al
    . The “Hygiene hypothesis” and the sharp gradient in the incidence of autoimmune and allergic diseases between Russian Karelia and Finland. APMIS 2013;121: 478–93.
    OpenUrl
  33. ↵
    1. Bach JF
    . The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911–20.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Lieberman D
    . The story of the human body: evolution, health and disease. New York: Vintage books; 2013.
  35. ↵
    1. Kotas ME,
    2. Medzhitov R
    . Homeostasis, inflammation, and disease susceptibility. Cell 2015;160:816–27.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Strehler BL,
    2. Mildvan AS
    . General theory of mortality and aging. Science 1960;132:14–21.
    OpenUrlFREE Full Text
  37. ↵
    1. Peto R,
    2. Roe FJ,
    3. Lee PN,
    4. et al
    . Cancer and ageing in mice and men. Br J Cancer 1975;32:411–26.
    OpenUrlCrossRefPubMed
    1. Sulak M,
    2. Fong L,
    3. Mika K,
    4. et al
    . TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants. eLife 2016;Sep 19;5.pii: e11994.
  38. ↵
    1. Tomasetti C,
    2. Li L,
    3. Vogelstein B
    . Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 2017;355:1330–4.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Tyner SD,
    2. Venkatachalam S,
    3. Choi J,
    4. et al
    . p53 mutant mice that display early ageing-associated phenotypes. Nature 2002;415:45–53.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Helgason A,
    2. Palsson S,
    3. Gudbjartsson DF,
    4. et al
    . An association between the kinship and fertility of human couples. Science 2008;319:813–6.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Williams GC,
    2. Nesse RM
    . The dawn of Darwinian medicine. Q Rev Biol 1991;66:1–22.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Ng SB,
    2. Turner EH,
    3. Robertson PD,
    4. et al
    . Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009;461:272–6.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Lander ES
    . The heroes of CRISPR. Cell 2016;164:18–28.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Gilmour D,
    2. Rembold M,
    3. Leptin M
    . From morphogen to morphogenesis and back. Nature 2017;541:311–20.
    OpenUrl
  45. ↵
    1. Ainsworth C
    . Secrets of life in a spoonful of blood. Nature 2017;542:156–8.
    OpenUrl
  46. ↵
    1. Chiu RW,
    2. Chan KC,
    3. Gao Y,
    4. et al
    . Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 2008;105:20458–63.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Haig D
    . Genetic conflicts in human pregnancy. Q Rev Biol 1993;68:495–532.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Crespi B,
    2. Stead P,
    3. Elliot M
    . Evolution in health and medicine Sackler colloquium: comparative genomics of autism and schizophrenia. Proc Natl Acad Sci U S A 2010; 107(Suppl 1):1736–41.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Byars SG,
    2. Stearns SC,
    3. Boomsma JJ
    . Opposite risk patterns for autism and schizophrenia are associated with normal variation in birth size: phenotypic support for hypothesized diametric gene–dosage effects. Proc Biol Sci 2014;281: 20140604.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Ayala FJ
    . “Nothing in biology makes sense except in the light of evolution”: Theodosius Dobzhansky: 1900–1975”. J Hered 1977;68:3–10.
    OpenUrlPubMed
  51. ↵
    1. Andersen H
    . Mechanisms: What are they evidence for in evidence-based medicine? J Eval Clin Pract 2012;18:992–9.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Nesse RM
    . Evolution: medicine’s most basic science. Lancet 2008;372:s21–7.
    OpenUrl
    1. Charlton BG
    . A syllabus for evolutionary medicine. J R Soc Med 1997;90:397–9.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Naugler CT
    . Evolutionary medicine: update on the relevance to family practice. Can Fam Physician 2008;54:1265–9.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 190 (6)
CMAJ
Vol. 190, Issue 6
12 Feb 2018
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The genome, microbiome and evolutionary medicine
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The genome, microbiome and evolutionary medicine
Robert C. Brunham
CMAJ Feb 2018, 190 (6) E162-E166; DOI: 10.1503/cmaj.170846

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The genome, microbiome and evolutionary medicine
Robert C. Brunham
CMAJ Feb 2018, 190 (6) E162-E166; DOI: 10.1503/cmaj.170846
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • What is evolutionary medicine’s view of disease?
    • How does evolutionary medicine view the patient?
    • How has the human genome evolved, and what are the implications for medicine?
    • What is the role of the evolving microbiome?
    • What are the categories of disease causation according to evolutionary medicine?
    • How can evolutionary medicine change our approach to practising medicine?
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • To what end, evolutionary medicine?
  • PubMed
  • Google Scholar

Cited By...

  • To what end, evolutionary medicine?
  • Google Scholar

More in this TOC Section

  • The case for a Canadian standard for 2SLGBTQIA+ medical education
  • Impaired driving and legalization of recreational cannabis
  • Rapid antigen screening of asymptomatic people as a public health tool to combat COVID-19
Show more Analysis

Similar Articles

Collections

  • Topics
    • Molecular medicine
    • Medical education, residency, internship
    • Infectious diseases
    • Genetics

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, CMA Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire